|
Chawnshang Chang
Dr. Chang’s research focuses on the Androgen Receptor (AR). His pioneer cloning of human and rat Androgen Receptor (Science-1988) represents the landmark discovery in the androgen-AR field that not only lead to identify the pathogenesis of Testicular Feminization Syndrome and SBMA Neuron Diseases, but also allows Urologists for the first time to monitor the AR status of processing prostate cancer and dissect the mechanisms for failure of androgen deprivation therapy. Dr. Chang then discovered the first AR coregulator (1996-PNAS) that lead to subsequent findings of more than 100 such coregulators and their function in the modulation of Androgen-AR functions in various diseases. In 2002 Dr. Chang’s lab generated the first floxed AR mouse (PNAS-2002) that knockouted AR in a selective cell and identify the first compound (ASC-J9) that selectively degraded AR in selective cells, that led to the development of first potential therapy to selectively target AR in SBMA Neuro disease (Nature Medicine-2007), Neutropenia (JEM-2009), bladder cancer (JNCI-2007), wound healing (JCI-2009) and hepatitis B-induced liver cancer (Science-TM-2010). By knockout AR in individual cell of prostate, Dr. Chang’s lab then discovered AR could function as suppressor to CK5-basal intermediate epithelial cell, as survivor to CK-8 luminal epithelial cell and as proliferator to stromal cell. These findings of differential AR function in individual cells of prostate not only help to explain why androgen deprivation therapy via systematic suppression androgen would fail, it also help to develop new drugs to target AR in selective prostate cell to battle prostate cancer. Dr. Chang published 306 papers in the AR-Urology/Oncology/Endocrinology field and trained more than 117 Ph.D. students/post Drs.; 60 of his trainees are now professors in various Universities.
More information...
|
